Keenova Therapeutics plc announced that it will present new survey findings on Dupuytren’s contracture and XIAFLEX collagenase clostridium histolyticum at the American Association for Hand Surgery Annual Meeting, scheduled for January 13 to 17, 2026. The presentation focuses on how patients perceive the condition and its available treatment options, while also identifying gaps in education that may affect treatment timing and outcomes.
Health Technology Insights: Allink Biotherapeutics Secures $47Million Series A Extension
The survey analysis offers a closer look at how patients understand Dupuytren’s contracture and how those perceptions influence decisions around care. The findings point to opportunities for improved patient education and earlier engagement with healthcare providers, which could help individuals recognize symptoms sooner and pursue appropriate treatment before the condition progresses.
Dr. Philip Blazar, a hand specialist, orthopedic surgeon, Professor of Orthopaedic Surgery at Harvard Medical School, and the presenting author, explained that the results reveal a clear need for better awareness of Dupuytren’s contracture. He noted that encouraging open discussions between patients and providers can help people seek care earlier. According to Dr. Blazar, providing clearer information and resources can improve recognition of the condition and support better outcomes for patients living with it.
Health Technology Insights: Cosette Pharma Launches First Generic CIPRO HC with CGT Exclusivity
The Keenova sponsored presentation is titled “A National Survey of Patient Perceptions, Attributes, and Satisfaction Related to Dupuytren’s Contracture Diagnosis and Treatment Options,” and includes analysis of surgery, collagenase clostridium histolyticum injections, and needle aponeurotomy. The study was conducted online in March 2024 and gathered responses from two hundred adults across the United States who had experience with Dupuytren’s contracture or its treatments.
Survey results showed that many respondents were unaware that Dupuytren’s contracture can be treated, and even among those diagnosed, treatment was often delayed. Patients who had received care reported the highest satisfaction with collagenase clostridium histolyticum injections, and many indicated they wished they had pursued treatment sooner. These findings highlight the importance of early diagnosis, informed decision making, and stronger communication between patients and healthcare providers to improve treatment experiences and outcomes.
Health Technology Insights: Victor Miller Joins NorthStar Medical Radioisotopes, LLC as Chief Financial Officer
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
